Get In Touch
Have any questions or comments about the content you see on this page?
Bringing the first of a new class of medicines to market was only the beginning of RNAi’s journey. Building on Alnylam’s pioneering work, the Futurists are identifying new targets for RNAi therapeutics beyond the liver and orphan diseases and are leveraging the company’s investment in genomics and data sciences to accelerate drug development. Through their efforts, the Futurists are expanding the role that RNAi-based medicines can play in treating human disease.
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.Proceed to Site